GSK Leads Target-Validation Collaboration With EBI And Wellcome Trust
This article was originally published in The Pink Sheet Daily
Executive Summary
Following its February participation in the NIH-led Accelerating Medicines Partnership, GSK now is joining with the European Bioinformatics Institute and Wellcome Trust Sanger Institute on a broad-based target-validation effort headquartered in the U.K. The collaboration’s work will be non-competitive and available to all.